FDA Clearance Tracker · K202703
Vascutek Gelsoft Plus ERS Vascular Graft
Last checked: Nov 20, 2026Latest source record: Apr 6, 2021 (this decision)Source: openFDAMethods & limitations
Decided
Apr 6, 2021
Substantially Equivalent
Time to decision
202 days
Received Sep 16, 2020. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Traditional
Device class
Class II
The decision
- FDA number
- K202703
- Device name
- Vascutek Gelsoft Plus ERS Vascular Graft
- Applicant
- Vascutek, Ltd.
- Applicant location
- Inchinnan, GB
- Received
- Sep 16, 2020
- Decided
- Apr 6, 2021
- Decision
- Substantially Equivalent
- Submission type
- Traditional
Device type
- Device class
- Class II
- Regulation
- 21 CFR 870.3450
- Specialty
- Cardiology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code DSY. The earliest in FDA's data is K760090, decided Jul 20, 1976.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K202703
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Vascutek, Ltd.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K241550 · Decided Feb 27, 2025 · 272 days after receipt
Device type: Prosthesis, Vascular Graft, Of 6mm And Greater Diameter (DSY) · Cardiology
K241070 · Decided Nov 15, 2024 · 210 days after receipt
Device type: Prosthesis, Vascular Graft, Of 6mm And Greater Diameter (DSY) · Cardiology
- Thoraflex HybridBreakthroughPMA
P210006 · Decided Apr 19, 2022 · 418 days after receipt
Device type: Hybrid stent graft, thoracic aortic lesion treatment (QSK) · Cardiology
3 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.